Foghorn to cut 40% of workforce after scrapping Lilly-partnered cancer drug

Foghorn Therapeutics discontinued development of its experimental cancer drug partnered with Eli Lilly after the candidate failed to demonstrate sufficient benefit in an early-stage clinical trial. The setback removes a pipeline asset and creates negative implications for Foghorn's oncology development outlook, with more limited impact on Lilly.